Bellicum Pharmaceuticals, Inc. (BLCM) CFO Sells $61,377.34 in Stock
Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) CFO Alan A. Musso sold 6,206 shares of Bellicum Pharmaceuticals stock in a transaction dated Monday, November 27th. The shares were sold at an average price of $9.89, for a total transaction of $61,377.34. The sale was disclosed in a filing with the SEC, which is available through this link.
Shares of Bellicum Pharmaceuticals, Inc. (BLCM) traded up $0.02 during mid-day trading on Wednesday, reaching $9.75. 214,000 shares of the company traded hands, compared to its average volume of 600,214. Bellicum Pharmaceuticals, Inc. has a 12-month low of $7.41 and a 12-month high of $20.19. The company has a quick ratio of 6.08, a current ratio of 6.08 and a debt-to-equity ratio of 0.23.
Bellicum Pharmaceuticals (NASDAQ:BLCM) last announced its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.71) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.74) by $0.03. Bellicum Pharmaceuticals had a negative net margin of 17,957.31% and a negative return on equity of 77.16%. The firm had revenue of $0.13 million during the quarter, compared to the consensus estimate of $0.03 million. During the same period last year, the firm posted ($0.66) EPS. The firm’s quarterly revenue was up 18.2% on a year-over-year basis. equities research analysts expect that Bellicum Pharmaceuticals, Inc. will post -2.94 EPS for the current fiscal year.
Institutional investors and hedge funds have recently bought and sold shares of the business. Voya Investment Management LLC acquired a new stake in Bellicum Pharmaceuticals in the 2nd quarter valued at about $132,000. Commonwealth Equity Services Inc acquired a new stake in Bellicum Pharmaceuticals in the 3rd quarter valued at about $142,000. American International Group Inc. increased its position in Bellicum Pharmaceuticals by 7.1% in the 1st quarter. American International Group Inc. now owns 12,902 shares of the biopharmaceutical company’s stock valued at $159,000 after acquiring an additional 852 shares in the last quarter. Cubist Systematic Strategies LLC acquired a new stake in Bellicum Pharmaceuticals in the 3rd quarter valued at about $164,000. Finally, Nationwide Fund Advisors increased its position in Bellicum Pharmaceuticals by 30.4% in the 2nd quarter. Nationwide Fund Advisors now owns 15,530 shares of the biopharmaceutical company’s stock valued at $181,000 after acquiring an additional 3,620 shares in the last quarter. Hedge funds and other institutional investors own 54.38% of the company’s stock.
About Bellicum Pharmaceuticals
Bellicum Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing cellular immunotherapies for various forms of cancer, including hematological cancers and solid tumors, as well as orphan inherited blood disorders. The Company uses its chemical induction of dimerization (CID) technology platform to engineer and then control components of the immune system.
Receive News & Stock Ratings for Bellicum Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellicum Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.